BioSpace News Archive

CEI Vision Partners announces Carl Berglind has been named Vice President of Mergers and Acquisitions. He will lead CVP’s newly formed M&A function.

Awareness programs by non-profit organization about the actinic keratosis treatment have increased the awareness level among the people about the actinic keratosis treatment in developed economies, which is consequently expected to increase the value of actinic keratosis treatment market

Imcyse, who develop active specific immunotherapies for the treatment and prevention of severe chronic diseases, today announces the successful enrolment of 41 patients with recent-onset type 1 diabetes into its first-in-human Phase 1b study.

Absolute Antibody Ltd., specialists in antibody sequencing, engineering and recombinant expression with a vision to make recombinant antibody technology accessible to all, today announced the opening of a new facility in northeast England.

DJO®, a leading provider of medical technologies designed to get and keep people moving, announced the partnership with SirenMD, becoming the exclusive sales representative for SirenMD’s sports team market.

Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, presents its broad viral vector expertise and their potential to transform the fight against cancer at the annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held November 7-11 in Washington DC (USA).

- Simultaneously improved economy, enlargement and performance through revolutionary process design -

Titan will use the proceeds to drive the next stage of growth of the company through product line additions, sales team expansion, and accelerated research and development.

Kim Sablich, Chief Commercial Officer, and Jeff Nornhold, Senior Vice President, Pharmaceutical Operations & Development, join Myovant’s Executive Committee

TITAN Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15 at 2:00 p.m. Eastern time.